Investment Rating - The report does not explicitly state the investment rating for Hansoh Pharma Core Insights - Hansoh Pharma achieved revenue of RMB 15.0 billion in FY25, representing a 23% year-over-year increase. Innovative drug revenue reached RMB 10.2 billion (+30% YoY), while generic drug revenue was RMB 2.7 billion (-4% YoY). Collaboration revenue amounted to RMB 2.1 billion (+35% YoY) [1][4][5] - The proportion of innovative drug and collaboration income increased to 82% of total revenue, indicating a strong focus on innovative products [1][4] - The gross margin stood at 90.0%, down 1 percentage point year-over-year, while the operating profit margin increased by 4 percentage points to 36% due to improved selling expense ratios [5] - The net profit attributable to shareholders was RMB 5.56 billion, reflecting a 27% increase year-over-year, aligning with market expectations [1][5] Segment Analysis - Oncology revenue was RMB 10.0 billion (+23% YoY), accounting for 66% of total revenue. Anti-infective revenue was RMB 1.6 billion (+8% YoY), making up 12% of total revenue. Central nervous system revenue was RMB 1.3 billion (-5% YoY), representing 11% of total revenue. Metabolic and other diseases revenue was RMB 2.2 billion (+67% YoY), also accounting for 11% of total revenue [3][8] - Key milestones include the approval of Aumolertinib for first-line treatment in January 2026, expected to be included in the National Reimbursement Drug List in 2027. The company also completed three overseas licensing deals with a total transaction value exceeding USD 4.54 billion [6][8] - In 2025, the company advanced 8 new innovative drug candidates into clinical development and initiated 7 pivotal Phase III registrational clinical trials [6][8]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of approximately 642 million RMB for 2025, representing a year-on-year increase of 14.99%. The adjusted net profit was about 342 million RMB, up by 5.7% year-on-year, while the net profit attributable to the parent company was approximately 334 million RMB, reflecting a 6.1% increase year-on-year [2][3] - The growth in the precision marketing business product count reached 29% in 2025, although profit growth lagged behind revenue growth due to a decline in other income. The average monthly active users on the platform reached 3.02 million, a 14% increase year-on-year [3] - The company has established a high-quality "gold standard data" corpus covering over 10 million academic papers and numerous authoritative clinical guidelines, which supports its AI applications in the medical field [3] - The company forecasts revenues of approximately 743 million RMB, 868 million RMB, and 1.015 billion RMB for 2026, 2027, and 2028, respectively, with corresponding net profits of 358 million RMB, 402 million RMB, and 457 million RMB [3][5] Financial Summary - For 2025, the total revenue is projected at 642 million RMB, with a growth rate of 15%. The net profit attributable to the parent company is expected to be 334 million RMB, with a growth rate of 6% [5] - The gross margin for 2025 is approximately 60.02%, with a projected decline to 59.97% in the following years [5] - The company’s return on equity (ROE) is expected to increase from 6.87% in 2025 to 8.29% by 2028 [5] Earnings Forecast - The earnings per share (EPS) is projected to be 0.46 RMB for 2025, increasing to 0.62 RMB by 2028 [5] - The price-to-earnings (P/E) ratio is expected to decrease from 18.72 in 2025 to 11.46 by 2028, indicating a potentially more attractive valuation over time [5]

Investment Rating - The report maintains a "BUY" rating for Xunfei Healthcare, indicating potential returns of over 15% over the next 12 months [12]. Core Insights - Xunfei Healthcare reported FY25 revenue of RMB 915 million, reflecting a year-on-year growth of 24.7%, which was approximately 4% below estimates due to slower G-end growth in the second half of the year [1]. - The G-end growth decelerated significantly from 87% YoY in 1H25 to 4% YoY in 2H25, primarily due to centralized provincial procurement affecting project pricing [1]. - The B-end business showed robust recovery in 2H25, achieving a full-year growth of 31.1% YoY after a weaker first half [1]. - The attributable net loss narrowed by 51.1% YoY to RMB 65 million, driven by improved operating leverage [1]. - The company is focusing on solidifying its G-end leadership, accelerating B-end hospital penetration, and leveraging GBC synergy to develop C-end patient services as a long-term growth engine [1]. Financial Performance - Revenue projections for FY26E, FY27E, and FY28E are RMB 1,119 million, RMB 1,347 million, and RMB 1,599 million respectively, with YoY growth rates of 22.3%, 20.4%, and 18.7% [2]. - The attributable net profit is expected to improve from a loss of RMB 65 million in FY25 to a loss of RMB 40 million in FY26E, narrowing further to RMB 21 million in FY27E, and turning positive with a profit of RMB 3 million in FY28E [2]. - The earnings per share (EPS) is projected to improve from a loss of RMB 0.54 in FY25 to a loss of RMB 0.33 in FY26E, and finally to a profit of RMB 0.03 in FY28E [2]. Market Position and Strategy - Xunfei Healthcare has expanded its client base significantly, serving over 77,000 primary healthcare institutions and 600+ graded hospitals by the end of 2025 [1]. - The company achieved full coverage of its General Practice CDSS across all 90 counties in Zhejiang and secured its first out-of-province imaging cloud platform project in Guangxi [1]. - C-end patient management services revenue increased by 29% YoY to RMB 273 million, accounting for approximately 30% of total revenue, indicating a strategic shift towards a more recurring patient-paid business model [1]. - The communication conversion rate for paying patients reached 50% in 2025, with the Net Promoter Score (NPS) improving from 35% to 50% [1]. Valuation and Target Price - The target price for Xunfei Healthcare has been revised to HK$ 92.55, down from a previous target price of HK$ 143.59, reflecting a 33% upside from the current price of HK$ 69.60 [3]. - The target price is based on a price-to-sales (P/S) ratio of 9x for the 2026 estimates [1].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2025 met expectations, with total revenue reaching 7.224 billion yuan, a year-on-year increase of 15.3%, and net profit attributable to shareholders at 1.425 billion yuan, up 33.4% year-on-year [7] - The revenue from vegetable products, seasoning noodles, and other products for 2025 was 4.506 billion, 2.554 billion, and 164 million yuan respectively, with year-on-year growth rates of 33.7%, -4.3%, and -28.2% [7] - The company has shown significant improvement in gross margin, achieving 48.0% in 2025, with a marginal improvement to 48.8% in the second half of 2025 [7] - The company is continuously innovating its product offerings, introducing new flavors in the konjac category and expanding the flavor boundaries in seasoning noodles [7] - The earnings forecast for 2026-2028 has been slightly adjusted downwards, with net profits expected to be 1.68 billion, 1.89 billion, and 2.10 billion yuan respectively, reflecting year-on-year growth of 18%, 12%, and 11% [7] Financial Summary - Total revenue projections for 2024A to 2028E are 6.266 billion, 7.224 billion, 8.223 billion, 9.173 billion, and 10.095 billion yuan respectively, with corresponding year-on-year growth rates of 28.63%, 15.28%, 13.84%, 11.55%, and 10.05% [1] - The projected earnings per share (EPS) for 2024A to 2028E are 0.44, 0.59, 0.69, 0.78, and 0.86 yuan respectively [1] - The price-to-earnings (P/E) ratio for the current price and latest diluted EPS is projected to be 19.06, 14.29, 12.13, 10.81, and 9.70 for the years 2024A to 2028E [1]

Investment Rating - The investment rating for the company is "Buy" with a target price of 16.30 RMB, indicating an upside potential of 13.8% from the current stock price of 14.32 RMB [7][10]. Core Insights - The company's revenue for FY25 is projected to decline by 21.8% year-on-year to 148.06 billion RMB, with net profit attributable to shareholders decreasing by 20.0% to 14.5 billion RMB. The decline is primarily due to a slight decrease in self-produced coal sales volume and a significant drop in sales prices [3]. - The coal market's supply-demand dynamics are gradually improving, with coal prices in China rebounding after a prolonged decline. This trend is supported by government measures to strengthen capacity checks and policies in coal-exporting countries [4]. - Geopolitical risks in Iran are expected to boost coal demand as coal can serve as a substitute for oil and natural gas, further enhancing the coal market's supply-demand structure [5]. - The coal chemical business, accounting for approximately 12% of total revenue, is anticipated to provide additional momentum for the company's performance in 2026, with expectations of earnings recovery to 2024 levels [6]. Financial Summary - Revenue and net profit projections for the company from FY22 to FY26 are as follows: - FY22 Revenue: 220.58 billion RMB - FY23 Revenue: 192.97 billion RMB - FY24 Revenue: 189.4 billion RMB - FY25 Revenue: 148.1 billion RMB - FY26E Revenue: 167.55 billion RMB - FY22 Net Profit: 19.74 billion RMB - FY23 Net Profit: 20.18 billion RMB - FY24 Net Profit: 18.16 billion RMB - FY25 Net Profit: 14.5 billion RMB - FY26E Net Profit: 17.67 billion RMB - FY26E Earnings per Share: 1.36 RMB [7].

Investment Rating - The report does not explicitly state an investment rating for Hansoh Pharma Core Insights - Hansoh Pharma achieved revenue of RMB 15.0 billion in FY25, representing a 23% year-over-year increase. Innovative drug revenue was RMB 10.2 billion (+30% YoY), while generic drug revenue was RMB 2.7 billion (-4% YoY). Collaboration revenue reached RMB 2.1 billion (+35% YoY) [1][4] - The proportion of innovative drug and collaboration income increased to 82% of total revenue, indicating a strong focus on innovative products [1][4] - The gross margin was 90.0%, down 1 percentage point year-over-year. R&D expenses were RMB 3.4 billion (+24% YoY), and selling expenses were RMB 4.1 billion (+7% YoY). The operating profit margin improved by 4 percentage points to 36% [5] - The net profit attributable to shareholders was RMB 5.56 billion (+27% YoY), aligning with expectations [5] Segment Analysis - Oncology revenue was RMB 10.0 billion (+23% YoY), accounting for 66% of total revenue [8] - Anti-infective revenue was RMB 1.6 billion (+8% YoY), making up 12% of total revenue [8] - Central nervous system (CNS) revenue was RMB 1.3 billion (-5% YoY), representing 11% of total revenue [8] - Revenue from metabolic and other diseases was RMB 2.2 billion (+67% YoY), also accounting for 11% of total revenue [8] Recent Milestones - In January 2026, Aumolertinib (Ameile) was approved for first-line treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC, expected to be included in the National Reimbursement Drug List in 2027 [6] - Aumolertinib has been approved for first-line treatment in the UK and EU, with commercialization rights granted to Glenmark in selected countries [6] - In 2025, the company completed three overseas licensing deals with a total transaction value exceeding USD 4.54 billion, enhancing its international presence [6] - The company advanced 8 new innovative drug candidates into clinical development and initiated 7 pivotal Phase III registrational clinical trials [6] - GSK, a partner, has initiated registrational Phase III clinical trials for B7-H3 ADC in SCLC and osteosarcoma, with plans for additional trials in 2026 [6]

Investment Rating - The report maintains a "Buy" rating for China Biologic Products (1177 HK) [7] Core Views - The company reported a revenue growth of 10.3% year-on-year to RMB 31.83 billion for FY25, with innovative product revenue increasing by 26.2% to RMB 15.2 billion, accounting for 47.8% of total revenue [1] - Adjusted net profit grew by 31.4% year-on-year to RMB 4.54 billion, and if excluding dividends from Sinovac, the adjusted net profit still increased by 15% [1] - The company’s FY25 revenue was below expectations by 7.4% compared to the report's forecast and 3.9% compared to Bloomberg consensus, while adjusted net profit fell short by 27.5% and 9.0% respectively, mainly due to a milestone payment from Merck not being recognized as expected [1] - The company is expected to continue steady growth in FY26, driven by stable generic drug revenue and ongoing sales momentum from innovative drugs [1] Financial Summary - FY24A revenue is projected at RMB 28.87 billion, with a year-on-year growth of 10.2%, and FY25A revenue at RMB 31.83 billion, with a growth of 10.3% [2] - Adjusted net profit for FY26E is estimated at RMB 4.79 billion, reflecting a growth of 5.4% [2] - The adjusted earnings per share for FY26E is expected to be RMB 0.26, with a projected adjusted P/E ratio of 20.7 times [2] Target Price and Market Performance - The target price is set at HKD 8.70, down from the previous target of HKD 9.40, indicating a potential upside of 47.7% from the current price of HKD 5.89 [3] - The company has a market capitalization of HKD 110.5 billion and a 52-week price range of HKD 9.01 to HKD 3.34 [3] Shareholder Structure - Major shareholders include Xie Chengrun with 21.6% and Zheng Xiangling with 15.8% [4] Price Performance - The stock has shown a negative absolute return of -2.6% over the past month and -8.3% over the past three months [5]

Investment Rating - The report maintains a BUY rating for Innovent Biologics with a target price of HK$113.86, reflecting a potential upside of 33.2% from the current price of HK$85.50 [3]. Core Insights - Innovent Biologics reported its first-ever full-year net profit of RMB834 million for FY25, with revenue reaching RMB13.0 billion, representing a 38% year-over-year growth. Product sales increased by 45% year-over-year to RMB11.9 billion [1]. - The company is advancing its transition to a fully integrated global biopharma through strategic partnerships, including a collaboration with Takeda for IBI363 and a US$350 million upfront payment from Eli Lilly for early-stage assets [5]. - Innovent's product gross margin improved to 86.2% in 2H25, and the selling expense ratio decreased to 48.0% for FY25, despite a slight increase in 2H25 [1]. - The company has a strong pipeline with plans to advance at least five assets into global Phase 3 multi-regional clinical trials (MRCTs) by 2030, including IBI363 and IBI324, which is expected to disrupt the global retinal market [5]. - R&D expenses are projected to rise as global MRCTs advance, with a cash reserve of RMB24.3 billion as of the end of 2025, positioning Innovent well for its global ambitions [1]. Financial Summary - FY25 revenue was RMB13.0 billion, with a year-over-year growth of 38% and net profit of RMB834 million [1]. - Revenue projections for FY26, FY27, and FY28 are RMB16.6 billion, RMB20.9 billion, and RMB26.1 billion, respectively, with corresponding year-over-year growth rates of 27.6%, 25.7%, and 24.7% [2]. - The report indicates that net profit is expected to reach RMB2.1 billion in FY26, RMB3.4 billion in FY27, and RMB4.6 billion in FY28 [2]. Share Performance - The market capitalization of Innovent Biologics is approximately HK$148.36 billion, with an average turnover of HK$944 million over the past three months [3]. - The stock has shown a 1-month absolute performance of 0.5% and a 3-month performance of 5.9% [5].

Investment Rating - The report maintains a BUY rating for Akeso with a target price of HK$185.80, representing a 47.0% upside from the current price of HK$126.40 [3][9]. Core Insights - Akeso delivered strong product sales of RMB3.0 billion in FY25, reflecting a 52% year-over-year growth, closely aligning with previous estimates of RMB3.1 billion. This growth was primarily driven by the inclusion of cadonilimab and ivonescimab in the NRDL in January 2025 [1][2]. - Revenue growth is expected to accelerate further in FY26, supported by additional NRDL inclusions for major front-line indications [1]. - The company demonstrated operational leverage, with selling and R&D expenses as a percentage of product sales decreasing to 47% and 51%, respectively, from 49% and 56% in FY24 [1]. - Despite a reported net loss of RMB1.14 billion in FY25, Akeso maintains a robust balance sheet with RMB9.2 billion in cash and equivalents, providing a strong foundation for its late-stage clinical programs [1][2]. Financial Summary - Revenue projections for FY26 are estimated at RMB5.01 billion, with a year-over-year growth of 63.9%, followed by RMB8.68 billion in FY27 and RMB11.46 billion in FY28 [2][13]. - The net profit is projected to improve to RMB725.3 million in FY27 and RMB1.63 billion in FY28, after a loss of RMB733.7 million in FY26 [2][13]. - The gross profit margin is expected to normalize to 79% in FY25, down from 86% in FY24, due to price cuts associated with NRDL inclusions [1][2]. Clinical Development and Strategic Initiatives - Akeso is anticipating pivotal data readouts for ivonescimab, which has already met its primary PFS endpoint in a Phase 3 trial, showing a median PFS of 11.1 months compared to 6.9 months for the comparator [1][9]. - The company is advancing the global footprint of cadonilimab through pivotal trials, including a global Phase 2 trial for IO-resistant 2L HCC and a Phase 3 trial for 1L GC [1][9]. - Akeso's strategy includes the development of proprietary ADCs, with ongoing Phase 2 trials for HER3 ADC and TROP2/Nectin-4 ADC, aiming to evaluate combinatorial regimens with existing therapies [1][9].

Investment Rating - The report maintains a "Buy" rating for Anta Sports (02020.HK) [1] Core Views - Anta Sports achieved a revenue of 80.22 billion RMB in 2025, representing a year-on-year growth of 13.3%. However, the net profit attributable to shareholders decreased by 12.9% to 13.59 billion RMB. Excluding the impact of the previous year's Amer Sports listing and dilution, the net profit increased by 13.9% year-on-year [8] - The company is optimistic about its multi-brand strategy, which is expected to sustain growth. The report highlights the strong performance of the outdoor segment and the successful brand repositioning of FILA [8] - The report projects that Anta's revenue will continue to grow, with forecasts of 88.61 billion RMB in 2026 and 97.49 billion RMB in 2027, although growth rates are expected to slow down in the coming years [1][8] Financial Summary - Revenue Forecasts: - 2024: 70.83 billion RMB - 2025: 80.22 billion RMB - 2026: 88.61 billion RMB - 2027: 97.49 billion RMB - 2028: 107.14 billion RMB - Net Profit Forecasts: - 2024: 15.60 billion RMB - 2025: 13.59 billion RMB - 2026: 15.60 billion RMB - 2027: 15.71 billion RMB - 2028: 17.48 billion RMB - Earnings Per Share (EPS): - 2024: 5.58 RMB - 2025: 4.86 RMB - 2026: 5.58 RMB - 2027: 5.62 RMB - 2028: 6.25 RMB - Price-to-Earnings (P/E) Ratios: - 2024: 11.93 - 2025: 13.69 - 2026: 11.93 - 2027: 11.84 - 2028: 10.64 [1][8][9] Brand Performance - Anta Brand: Revenue of 34.75 billion RMB in 2025, with a year-on-year growth of 3.7%. The brand is focusing on channel reform and product innovation, with a gross margin of 53.6% [8] - FILA: Revenue of 28.47 billion RMB in 2025, with a year-on-year growth of 6.9%. The brand is implementing the "ONE FILA" strategy, focusing on high-end sports fashion [8] - Other Brands: Revenue of 17.00 billion RMB in 2025, with a significant growth of 59.2%. DESCENTE surpassed 10 billion RMB in revenue [8] Profitability and Valuation - The report anticipates that the profitability of Anta Sports will be impacted in the short term due to the consolidation of the Jack Wolfskin brand. However, it expects a significant one-time gain from the Amer Sports placement in 2026, estimated at around 1.6 billion RMB [8] - The adjusted net profit forecasts for 2026 and 2027 are 15.60 billion RMB and 15.71 billion RMB, respectively, with a projected P/E ratio of 12 for 2026 and 11 for 2027 [8][9]